



Veritas Pharma Announces Debt Settlement

VANCOUVER, British Columbia, October 29, 2020 -- **Veritas Pharma Inc.** (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ("**Veritas**" or the "**Company**") wishes to announce that it has entered into a debt settlement agreement to settle a disputed legal action by the issuance of a non-interest bearing convertible note in the principal amount of \$85,000. The principal amount of the note is automatically convertible into common shares of the Company based on the closing price of the Company's common shares on the Canadian Securities Exchange on the date the Company's common shares are reinstated for trading, less the maximum discount permitted by the policies of the Canadian Securities Exchange, and subject to a minimum price of \$0.15 per share.

About Veritas Pharma

Veritas has developed some intellectual property relating to various cannabis strains. It is the Company's aim to advance the science behind medical cannabis, by developing the most effective cannabis-based treatments for specific disease conditions and to acquire income-producing assets in the cannabis industry. The Company's mission is to commercialize its proprietary cannabis products. In addition, Veritas aims to utilize its expertise to enter into mergers and acquisitions with various cannabis industry participants in order to generate revenue by the end of 2020.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Securities Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors

Peter McFadden
Interim Chief Executive Officer & CFO

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com, and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc. Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.